Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Abstract Background This prospective study aims to investigate the efficacy and safety of pyrotinib (P) combined with 4 cycles of epirubicin and cyclophosphamide followed by 4 cycles of taxane and trastuzumab (P + EC-TH) regimen as neoadjuvant therapy for human epidermal growth factor receptor 2 (HE...
| الحاوية / القاعدة: | World Journal of Surgical Oncology |
|---|---|
| المؤلفون الرئيسيون: | , , , , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
BMC
2023-12-01
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1186/s12957-023-03266-5 |